Sign In
Buy CRVS
$11.60
-0.0900 (-0.770%)
At Close: Jun 03, 2026
Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases There are currently no fully approved agents for the treatment of relapsed PTCL and soquelit
Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
04:05pm, Tuesday, 03'rd Sep 2024
BURLINGAME, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president
Corvus Pharmaceuticals Eyes Phase 3 Trials: Soquelitinib's Promise In PTCL
07:03am, Tuesday, 03'rd Sep 2024
Corvus Pharmaceuticals' lead candidate, Soquelitinib, is advancing towards a Phase 3 trial for PTCL, set to begin in September 2024. Soquelitinib has shown a 26% Complete Response Rate [CRR] in early
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2024 Earnings Call Transcript
10:22pm, Friday, 09'th Aug 2024
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, IR Richard Miller - Chief Executive Officer Lei
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
04:01pm, Tuesday, 06'th Aug 2024
Early Results from Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Demonstrate Clinical Activity and Corresponding Changes in Cytokine Levels Consistent with ITK Inhibition Mechanism of Act
Soquelitinib registrational Phase 3 clinical trial in PTCL advancing toward initial enrollment in Q3 2024 Fast track designation underscores unmet need for patients with relapsed or refractory PTCL, a
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024
08:30am, Wednesday, 31'st Jul 2024
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
Corvus Pharmaceuticals Is Ready To Take Flight
06:53am, Thursday, 20'th Jun 2024
Corvus Pharmaceuticals has shown positive growth and maturity over the past six months, with new leadership and increased clinical trial activity. The company is expanding its label and IP development
The 2024 Millionaire's Club: 3 Penny Stocks to Buy Now
10:00am, Friday, 31'st May 2024
One of the best ways to spot opportunities in penny stocks to buy is by following insiders. Most notably, insiders who are putting their money where their mouth is.
Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference
04:02pm, Thursday, 30'th May 2024
BURLINGAME, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president a
Corvus Pharmaceuticals, Inc. (CRVS) Q1 2024 Earnings Call Transcript
07:53pm, Monday, 06'th May 2024
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Zack Kubow - Real Chemistry Richard Miller - President and CEO, Co-Founder Leiv
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
04:01pm, Monday, 06'th May 2024
Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024
04:02pm, Thursday, 02'nd May 2024
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
08:30am, Thursday, 02'nd May 2024
BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today announced
Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks
10:36am, Wednesday, 17'th Apr 2024
The heavy selling pressure might have exhausted for Corvus (CRVS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in
